Repligen Corp Files 8-K on Officer/Director Changes
Ticker: RGEN · Form: 8-K · Filed: Sep 2, 2025 · CIK: 730272
| Field | Detail |
|---|---|
| Company | Repligen Corp (RGEN) |
| Form Type | 8-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01, $395,000, $150,000, $750,000, $500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: officer-changes, director-changes, governance
TL;DR
Repligen's 8-K shows leadership changes, including officer appointments and director elections.
AI Summary
Repligen Corporation filed an 8-K on September 2, 2025, reporting events as of September 1, 2025. The filing indicates changes related to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: medium — Changes in key personnel and board composition can introduce uncertainty and signal strategic shifts, warranting closer monitoring.
Key Players & Entities
- Repligen Corporation (company) — Registrant
- September 1, 2025 (date) — Earliest event reported
- September 2, 2025 (date) — Date of report
FAQ
What specific officer positions were affected by the changes reported in this 8-K?
The filing indicates the appointment of certain officers and potential departures of certain officers, but does not specify the exact positions in the provided text.
Were any new directors elected to the Repligen Corporation board?
Yes, the filing explicitly states 'Election of Directors' as an item of information.
What is the primary business of Repligen Corporation?
Repligen Corporation is in the business of Biological Products (No Diagnostic Substances), with SIC code 2836.
When is Repligen Corporation's fiscal year end?
Repligen Corporation's fiscal year ends on December 31.
What is the principal executive office address for Repligen Corporation?
The principal executive offices are located at 41 Seyon Street, Building 1, Suite 100, Waltham, Massachusetts, 02453.
Filing Stats: 927 words · 4 min read · ~3 pages · Grade level 12.9 · Accepted 2025-09-02 08:55:12
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share RGEN Nasdaq Global Select
- $395,000 — tee") approved an annual base salary of $395,000, effective as of the Effective Date, an
- $150,000 — e Date, and a one-time signing bonus of $150,000. Ms. Hughes will also be eligible for a
- $750,000 — uity award worth an aggregate amount of $750,000, $500,000 of which will be granted in t
- $500,000 — worth an aggregate amount of $750,000, $500,000 of which will be granted in the form of
- $250,000 — the form of restricted stock units and $250,000 of which will be granted in the form of
Filing Documents
- d932295d8k.htm (8-K) — 26KB
- 0001193125-25-193481.txt ( ) — 135KB
- rgen-20250901.xsd (EX-101.SCH) — 3KB
- rgen-20250901_lab.xml (EX-101.LAB) — 17KB
- rgen-20250901_pre.xml (EX-101.PRE) — 11KB
- d932295d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIGEN CORPORATION Date: September 2, 2025 By: /s/ Olivier Loeillot Olivier Loeillot President and Chief Executive Officer